✦ The floor
Discussion
Signed responses from readers of the wire.
✦ Clinical Takeaway ✦
No immediate practice change indicated; audiologists should remain aware that OTC access has not resolved barriers to benefit and that counseling and follow-up still add value for OTC users who seek professional guidance.
✦ Why It Matters ✦
This JAMA commentary signals growing expert consensus that OTC hearing aid policy reform needs complementary measures—such as consumer education, outcome monitoring, and professional touchpoints—to translate regulatory intent into real-world hearing health gains.
✦ Key Points ✦
- 01Published in JAMA four years after the 2022 FDA OTC hearing aid rule took effect.
- 02Authors argue regulatory reform alone is insufficient to ensure consumer benefits.
- 03Implies that access, affordability, education, and support structures remain unresolved.
- 04Raises questions about follow-up policy, public health outreach, and professional roles.
- 05Relevant to audiologists, policymakers, and hearing aid manufacturers monitoring OTC outcomes.
✦ Claims & Evidence ✦
ClaimEvidenceSupport
Regulatory reform alone is insufficient to ensure consumer benefits from OTC hearing aids.
opinionpartially supported✦ Research metadata ✦
- PMID
- 42879164
- DOI
- 10.1001/jama.2026.19796.
- Journal
- JAMA
- Publication type
- editorial
- Evidence level
- 5
- Intervention
- OTC hearing aid regulatory policy
Primary outcomes
Assessment of whether OTC regulatory reform has produced consumer benefits